Peripheral CD4+ T-Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor-Associated Immune Modulation in B-Cell Lymphoma. (PubMed, Hematol Oncol) - Oct 11, 2026 - "In an exploratory real-world observation, three patients received BTK inhibition before glofitamab; all achieved complete responses, with two remaining in remission at data cutoff and one relapsing after 8.4 months. These findings identify peripheral CD4+ T-cell reserve as a potential biomarker associated with BsAb outcomes and provide a rationale for further investigation of BTK inhibitor-mediated immune modulation in BsAb treatment strategies."
Biomarker • Journal • Retrospective data • B Cell Lymphoma • Hematological Malignancies • Immune Modulation • Immunology • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD20 • CD4 • CD8 • IFNG • IL2
|
|
Dingyao Hu; Hui Yu; Jiaowu Cao; Jie Chen; Jie Lv; Jin Chai; Jun Zhu; Wenhui Zhang; Yanxiang Li; Yue Wang; Yuqin Song; Zhao Jin
|